Crinetics Pharmaceuticals(CRNX) - 2025 Q3 - Quarterly Results

Exhibit 99.1 Crinetics Pharmaceuticals Reports Third Quarter 2025 Financial Results and Provides Business Update PALSONIFY™ (Paltusotine) Launched in the U.S. with Encouraging Early Feedback from Patients and Physicians, and Positive Reimbursement Trends Reiterates Cash Burn of $340-370M and Cash Runway into 2029 Management Hosting Conference Call at 4:30 p.m. ET Today SAN DIEGO – November 6, 2025 – Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX), a global pharmaceutical company focused on the discovery, dev ...